Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBT Margin: 2011-2025

Historic EBT Margin for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to 47.87%.

  • Catalyst Pharmaceuticals' EBT Margin rose 342.00% to 47.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.43%, marking a year-over-year increase of 843.00%. This contributed to the annual value of 43.98% for FY2024, which is 2025.00% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' EBT Margin is 47.87%, which was up 1.25% from 47.28% recorded in Q2 2025.
  • Catalyst Pharmaceuticals' EBT Margin's 5-year high stood at 54.33% during Q4 2022, with a 5-year trough of -37.03% in Q3 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median EBT Margin value was 45.46% (recorded in 2024), while the average stood at 37.72%.
  • In the last 5 years, Catalyst Pharmaceuticals' EBT Margin tumbled by 8,246bps in 2023 and then soared by 8,148bps in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBT Margin (Quarterly) stood at 33.45% in 2021, then spiked by 2,088bps to 54.33% in 2022, then crashed by 1,209bps to 42.24% in 2023, then skyrocketed by 1,006bps to 52.31% in 2024, then surged by 342bps to 47.87% in 2025.
  • Its EBT Margin was 47.87% in Q3 2025, compared to 47.28% in Q2 2025 and 50.41% in Q1 2025.